Trial Outcomes & Findings for PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate (NCT NCT03222128)

NCT ID: NCT03222128

Last Updated: 2025-01-03

Results Overview

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

1074 participants

Primary outcome timeframe

1 year

Results posted on

2025-01-03

Participant Flow

Subjects were screened and enrolled at 51 sites in the US

The As-Treated population was 1074 The Valve-Implanted population was 1069

Participant milestones

Participant milestones
Measure
PIIS3i - SAPIEN 3
PIIS3i - SAPIEN 3 is Operable Group TAVR: Implantation of the SAPIEN 3
Overall Study
STARTED
1074
Overall Study
Valve-Implanted
1069
Overall Study
COMPLETED
968
Overall Study
NOT COMPLETED
106

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PIIS3i - SAPIEN 3
n=1074 Participants
PIIS3i - SAPIEN 3 is Operable Group TAVR: Implantation of the SAPIEN 3
Age, Continuous
81.9 years
STANDARD_DEVIATION 6.6 • n=5 Participants
Sex: Female, Male
Female
412 Participants
n=5 Participants
Sex: Female, Male
Male
662 Participants
n=5 Participants
STS Score
5.3 units on a scale
STANDARD_DEVIATION 1.29 • n=5 Participants
NYHA Classification III/IV
780 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 year

Population: AI as a factor in this value; only 964/1069 patients had ECHO data.

Outcome measures

Outcome measures
Measure
PIIS3i - SAPIEN 3
n=964 Participants
PIIS3i - SAPIEN 3 is Operable Group TAVR: Implantation of the SAPIEN 3
Number of Participants With Composite of All-cause Death, All Stroke and Aortic Insufficiency (AI) ≥ Moderate
125 Participants

SECONDARY outcome

Timeframe: 30 Days

Outcome measures

Outcome measures
Measure
PIIS3i - SAPIEN 3
n=1069 Participants
PIIS3i - SAPIEN 3 is Operable Group TAVR: Implantation of the SAPIEN 3
Composite of All-cause Death, All Stroke, Life Threatening (Disabling)/ Major Bleeding and Major Vascular Complication at 30 Days
196 Participants

Adverse Events

PIIS3i - SAPIEN 3

Serious events: 592 serious events
Other events: 861 other events
Deaths: 75 deaths

Serious adverse events

Serious adverse events
Measure
PIIS3i - SAPIEN 3
n=1069 participants at risk
PIIS3i - SAPIEN 3 is Operable Group TAVR: Implantation of the SAPIEN 3
Metabolism and nutrition disorders
Abnormal lab value
2.1%
22/1069 • Number of events 26 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Dissection
1.0%
11/1069 • Number of events 11 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Distal embolization (noncerebral) from vascular sou
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Access site and access related vascular injury - Failure of percutaneous access site closure
0.75%
8/1069 • Number of events 8 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Hematoma
0.47%
5/1069 • Number of events 5 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Other
0.75%
8/1069 • Number of events 8 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Perforation
0.37%
4/1069 • Number of events 4 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Pseudoaneurysm
0.37%
4/1069 • Number of events 4 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Rupture
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Stenosis
0.47%
5/1069 • Number of events 5 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Access site and access related vascular injury - Ventricular rupture (Apical rupture)
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Blood and lymphatic system disorders
Anemia/Hemolytic anemia
2.3%
25/1069 • Number of events 29 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Anesthesia related complication - Confusion
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Anesthesia related complication - Other
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Angina/Cardiac chest pain
1.5%
16/1069 • Number of events 17 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Aortic Valve Stenosis
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Aortic insufficiency/Regurgitation PV leak - Non structural dysfunction
0.65%
7/1069 • Number of events 7 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
General disorders
Aortic insufficiency/Regurgitation PV leak - Structural dysfunction
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
General disorders
Aortic insufficiency/Regurgitation non valvular cause
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Arrhythmia/Conduction system injury (defect)
18.2%
195/1069 • Number of events 216 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Bleeding - Hemorrhage
10.4%
111/1069 • Number of events 134 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Cardiac arrest
1.6%
17/1069 • Number of events 17 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Cardiac tamponade/Pericardial effusion
1.3%
14/1069 • Number of events 14 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Cardiogenic shock
0.19%
2/1069 • Number of events 3 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Carotid artery disease
0.47%
5/1069 • Number of events 5 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Coronary artery disease/Coronary ischemia
0.75%
8/1069 • Number of events 11 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Coronary flow obstruction/Transvalvular flow disturbance
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Psychiatric disorders
Delirium
0.28%
3/1069 • Number of events 3 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Device migration/malposition requiring intervention
0.28%
3/1069 • Number of events 3 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Ear and labyrinth disorders
Edema
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Encephalopathy
0.28%
3/1069 • Number of events 3 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Metabolism and nutrition disorders
Exercise intolerance or weakness
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Gastrointestinal disorders
Gastro Intestinal event - Non-hemorrhagic
2.9%
31/1069 • Number of events 33 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Renal and urinary disorders
Genito-Urinary event - Non-hemorrhagic
1.6%
17/1069 • Number of events 17 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Heart failure/CHF/Low output failure
7.1%
76/1069 • Number of events 96 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
General disorders
Hemolysis
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Hypertension
0.94%
10/1069 • Number of events 10 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Hypotension
1.0%
11/1069 • Number of events 11 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Access site infection
0.37%
4/1069 • Number of events 4 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Bacteremia
0.47%
5/1069 • Number of events 5 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Endocarditis
0.75%
8/1069 • Number of events 8 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Other
2.4%
26/1069 • Number of events 27 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Respiratory infection
5.1%
55/1069 • Number of events 63 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Sepsis
2.6%
28/1069 • Number of events 29 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Urinary tract infection
1.9%
20/1069 • Number of events 21 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Investigations
Ischemia
0.75%
8/1069 • Number of events 10 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Myocardial Infarction
1.2%
13/1069 • Number of events 15 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Investigations
Mental state change (not neurological) - Confusion
0.47%
5/1069 • Number of events 5 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Investigations
Mental state change (not neurological) - Dementia
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Investigations
Mental state change (not neurological) - Depression
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Miscellaneous - Cancer
1.6%
17/1069 • Number of events 17 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Investigations
Miscellaneous - Drug reaction
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Miscellaneous - Fall
2.2%
23/1069 • Number of events 25 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
General disorders
Miscellaneous - Other
1.4%
15/1069 • Number of events 15 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Social circumstances
Miscellaneous - Suicide
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Mitral valve injury or insufficiency
0.28%
3/1069 • Number of events 3 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
General disorders
Multi organ failure
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Musculoskeletal - Fracture
3.1%
33/1069 • Number of events 36 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Musculoskeletal and connective tissue disorders
Musculoskeletal - Pain
2.3%
25/1069 • Number of events 25 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Change in level of consciousness
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Cognitive impairment
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Dysphasia/Aphasia
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Hemiparesis (One sided body weakness)
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Hemorrhagic stroke
0.75%
8/1069 • Number of events 8 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Ischemic stroke
2.2%
24/1069 • Number of events 25 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Other
0.56%
6/1069 • Number of events 7 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Other new neurological sign consistent with stroke
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - TIA
0.94%
10/1069 • Number of events 12 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Nervous system disorders
Neurological - Undetermined stroke
0.65%
7/1069 • Number of events 8 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Pericarditis
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Renal and urinary disorders
Renal insufficiency or renal failure
2.9%
31/1069 • Number of events 34 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Aspiration
0.19%
2/1069 • Number of events 3 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Atelectasis
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Dyspnea
1.4%
15/1069 • Number of events 15 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Other
1.6%
17/1069 • Number of events 18 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Pneumothorax
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Pulmonary edema
0.19%
2/1069 • Number of events 2 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Pulmonary effusion
1.6%
17/1069 • Number of events 17 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Respiratory failure
3.0%
32/1069 • Number of events 37 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Syncope
1.3%
14/1069 • Number of events 15 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Blood and lymphatic system disorders
Thrombocytopenia
1.3%
14/1069 • Number of events 15 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Thromboembolic event
1.2%
13/1069 • Number of events 13 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
General disorders
Unknown cause of death
0.47%
5/1069 • Number of events 5 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Valve thrombosis
0.09%
1/1069 • Number of events 1 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Vascular complication - Non-access related
1.5%
16/1069 • Number of events 18 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
General disorders
Other
3.6%
38/1069 • Number of events 41 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.

Other adverse events

Other adverse events
Measure
PIIS3i - SAPIEN 3
n=1069 participants at risk
PIIS3i - SAPIEN 3 is Operable Group TAVR: Implantation of the SAPIEN 3
Investigations
Abnormal lab value
13.5%
144/1069 • Number of events 186 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Blood and lymphatic system disorders
Anemia/Hemolytic anemia
12.0%
128/1069 • Number of events 140 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Aortic insufficiency/Regurgitation PV leak - Non structural dysfunction
5.1%
55/1069 • Number of events 55 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Arrhythmia/Conduction system injury (defect)
28.0%
299/1069 • Number of events 357 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Bleeding - Hemorrhage
19.8%
212/1069 • Number of events 240 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Gastrointestinal disorders
Gastro Intestinal event - Non-hemorrhagic
6.2%
66/1069 • Number of events 77 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Renal and urinary disorders
Genito-Urinary event - Non-hemorrhagic
7.8%
83/1069 • Number of events 88 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Cardiac disorders
Heart failure/CHF/Low output failure
8.9%
95/1069 • Number of events 101 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Hypertension
5.3%
57/1069 • Number of events 59 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Vascular disorders
Hypotension
5.9%
63/1069 • Number of events 68 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Other
5.1%
55/1069 • Number of events 62 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Infections and infestations
Infection - Urinary tract infection
8.1%
87/1069 • Number of events 101 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Injury, poisoning and procedural complications
Miscellaneous - Fall
6.5%
70/1069 • Number of events 81 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Investigations
Miscellaneous - Other
6.1%
65/1069 • Number of events 72 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Musculoskeletal and connective tissue disorders
Musculoskeletal - Pain
7.6%
81/1069 • Number of events 94 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Renal and urinary disorders
Renal insufficiency or renal failure
10.9%
117/1069 • Number of events 134 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Respiratory, thoracic and mediastinal disorders
Respiratory event - Pulmonary effusion
5.9%
63/1069 • Number of events 67 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Blood and lymphatic system disorders
Thrombocytopenia
9.4%
101/1069 • Number of events 101 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.
Investigations
Other
10.4%
111/1069 • Number of events 136 • The Adverse data collected and reported here are over a period of 1 Year Valve-implant population are noted here.
All Adverse Events are site-reported.

Additional Information

Director of Research

Edwards Lifesciences

Phone: 949-250-2500

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place